未登录

A

Akbar Ali

u mass chan medical school

H指数:30

被引数:3,389

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A method to synthesize analytical rhodoquinone standards for quantitative analysis in tissue specimen

一种用于组织样本定量分析中合成分析用 rhodoquinone 标准品的制备方法

Journal of Lipid Research

IF4.1

2026-07-090

OAAI

Fluorinated HIV-1 Protease Inhibitors Containing Chiral Hydroxyethylbenzene and Indanol as P2′ Ligands with Potent Activity Against Drug-Resistant Variants

含手性羟乙基苯和吲哚醇作为P2′配体的氟化HIV-1蛋白酶抑制剂，对耐药变异体具有显著活性

European Journal of Medicinal Chemistry

IF5.9

2025-12-190

PRE

Structural Analysis of Inhibitor Binding to Enterovirus-D68 3C Protease

IF3.5

2025-01-080

OAAI

Elucidating the Substrate Envelope of Enterovirus 68-3C Protease: Structural Basis of Specificity and Potential Resistance

IF3.5

2024-09-051

OAAI

HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2023-09-015

OAAI

Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance

IF0

2023-03-1510

OA

Phenylsulfamoyl Benzoic Acid Inhibitor of ERAP2 with a Novel Mode of Inhibition

具有新型抑制方式的ERAP2的苯基氨磺酰基苯甲酸抑制剂

ACS CHEMICAL BIOLOGY

IF3.8

2022-06-293

PRE

Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-08-1811

OA

Inhibiting HTLV-1 Protease: A Viable Antiviral Target

ACS CHEMICAL BIOLOGY

IF3.8

2021-02-2317

OAAI

Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188

IF3.5

2021-01-2594

OAAI

Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2020-07-166

OAAI

Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors

IF4.7

2020-04-2817

OAAI

Avoiding Drug Resistance by Substrate Envelope Guided Design: Toward Potent and Robust HCV N53/4A Protease Inhibitors

IF4.2

2020-04-190

OA

Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir

ACS CHEMICAL BIOLOGY

IF3.8

2019-12-2314

OAAI

Discovery of Selective Inhibitors of Endoplasmic Reticulum Aminopeptidase 1

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2019-12-1641

OAAI

HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2′ Ligands To Optimize Hydrogen Bonding in the Substrate Envelope

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2019-08-0624

OAAI

Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease (vol 5, pg 316, 2019)

ACS INFECTIOUS DISEASES

IF3.8

2019-04-162

OAAI

Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease

ACS INFECTIOUS DISEASES

IF3.8

2018-12-1327

OAAI

Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2018-05-1719

OAAI

Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2017-06-1939

OAAI